Persistent mutation burden drives sustained anti-tumor immune responses
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of …
to consistently demonstrate clinical utility in predicting responses in the context of …
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
Missense driver mutations in cancer are concentrated in a few hotspots. Various
mechanisms have been proposed to explain this skew, including biased mutational …
mechanisms have been proposed to explain this skew, including biased mutational …
The association between tumor mutational burden and prognosis is dependent on treatment context
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
survival after treatment with immune checkpoint inhibitors (ICIs). The association of TMB with …
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
The status of tumor mutational burden and immunotherapy
Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
MA Wood, BR Weeder, JK David, A Nellore… - Genome medicine, 2020 - Springer
Background Tumor mutational burden (TMB; the quantity of aberrant nucleotide sequences
a given tumor may harbor) has been associated with response to immune checkpoint …
a given tumor may harbor) has been associated with response to immune checkpoint …
Correlate tumor mutation burden with immune signatures in human cancers
X Wang, M Li - BMC immunology, 2019 - Springer
Background Tumor mutation burden (TMB) has been associated with cancer
immunotherapeutic response and cancer prognosis. Although many explorations have …
immunotherapeutic response and cancer prognosis. Although many explorations have …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
V Anagnostou, N Niknafs, K Marrone, DC Bruhm… - Nature cancer, 2020 - nature.com
Despite progress in immunotherapy, identifying patients that respond has remained a
challenge. Through analysis of whole-exome and targeted sequence data from 5,449 …
challenge. Through analysis of whole-exome and targeted sequence data from 5,449 …
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to
immune checkpoint inhibitors and has been shown to be more significantly associated with …
immune checkpoint inhibitors and has been shown to be more significantly associated with …